Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

Ph not_applicable

67%

Ph phase_4

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 4Post-market surveillance

1(33.3%)

N/ANon-phased studies

2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Phase 41 (33.3%)

N/A2 (66.7%)

Trials by Status

terminated133%

completed267%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_4

Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA

NCT03589833

terminatednot_applicable

Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

NCT00801268

completednot_applicable

Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid

NCT01161459

Clinical Trials (3)

Showing 3 of 3 trials

NCT03589833Phase 4

Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA

Completed

NCT00801268Not Applicable

Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

Terminated

NCT01161459Not Applicable

Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3